It's another Landmarks of OncoPharm episode looking at the carboplatin-paclitaxel regimen in ovarian cancer from 20 years ago.

carboplatin/paclitaxel vs. cisplatin/paclitaxel: https://pubmed.ncbi.nlm.nih.gov/?term=37643542

An experimental drug for EGFRm NSCLC, patritumab deruxtecan (HER3-DXd), raises some eyebrows and a new agent is FDA-approved for hematopoietic stem cell mobilization (motixafortide).

You read it in every solid tumor paper - RECIST - criteria. This Pod discusses some of the details of the Response Evaluation in Solid Tumors (RECIST) criteria along with the pros and cons of its use - including a modification of the criteria for use with immunotherapy.

Empiric dose reductions for variant DPYD alleles isn't necessarily new, but the outcomes of patients treated with those dose reductions isn't well described. Dutch researchers provide some much needed evidence.

Link: https://pubmed.ncbi.nlm.nih.gov/?term=37639651

Is there a role for ICIs in dMMR/MSI-h pancreatic cancer? This retrospective says, uh maybe probably.

Link: https://pubmed.ncbi.nlm.nih.gov/?term=37625102

A Foundations of OncoPharm episode on nab-paclitaxel, with a focus on the pharmaceutical differences from conventional paclitaxel.

A combination product is now available of niraparib + abiraterone for use in mCRPC.

Another BCMA-CD3 agent is approved for r/r multiple myeloma and melphalan hepatic arterial infusion for metastatic uveal melanoma is approved.

Talquetamab is approved for r/r multiple myeloma and the STOP-CA trials asks if atorvastatin can prevent anthracycline cardiotoxicity.

STOP-CA: https://jamanetwork.com/journals/jama/fullarticle/2807988

The Ruby trial leads to an FDA approval for dostarlimab + chemo in advanced/recurrent endometrial cancer, but only dMMR/MSI-H patients.

Quizartinib's label and REMS program provide some clear, but concerning, warnings about its toxicity.

By listener request! What is BCOP, why pursue it, and some simple tips on studying for the exam.

A Landmark of OncoPharm from 2004: FOLFIRI --> FOLFOX or FOLFOX --> FOLFIRI.

Some interesting dosing to discuss in this study.

Link: https://pubmed.ncbi.nlm.nih.gov/?term=37379692